Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04356339 (ClinicalTrials.gov)	November 24, 2020	19/4/2020	US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector	US PROmyBETAapp2.0: Ascertaining Medication Usage and Patient-reported Outcomes (PROs) Via the myBETAapp™ in Patients With Multiple Sclerosis Treated With BETASERON® Using BETACONNECT™ Autoinjector	Multiple Sclerosis	Drug: Interferon-beta -1b (BETASERON, BAY 86-5046)	Bayer	NULL	Completed	18 Years	N/A	All	100		United States
2	NCT03808142 (ClinicalTrials.gov)	February 20, 2019	10/1/2019	PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon	PROmyBETAappGame: Ascertaining Medication Usage & Patient Reported Outcomes Via the myBETAapp and Exploring Gamification in Patients With Multiple Sclerosis Treated With Betaferon	Multiple Sclerosis	Other: myBETAapp;Other: PEAK;Drug: Betaferon , BAY86-5046;Device: BETACONNECT	Bayer	NULL	Completed	18 Years	N/A	All	79		Germany
3	NCT03134573 (ClinicalTrials.gov)	September 15, 2017	26/4/2017	Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study	PROmyBETAapp: Ascertaining Medication Usage & Documentation of Patient Reported Outcomes Utilizing the myBETAapp® in Patients With Multiple Sclerosis Treated With Betaferon®: a Pilot Study	Multiple Sclerosis	Drug: Interferon beta -1b (Betaferon, BAY86-5046);Device: Betaconnect auto-injector;Device: myBETAapp	Bayer	NULL	Completed	18 Years	N/A	All	96		Germany
4	NCT02652091 (ClinicalTrials.gov)	February 5, 2016	5/1/2016	Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction	Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta -1b (Betaseron, BAY86-5046);Device: BETACONNECT device	Bayer	NULL	Completed	18 Years	N/A	All	146		United States
5	NCT02486640 (ClinicalTrials.gov)	September 8, 2015	15/6/2015	Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon	BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence	Multiple Sclerosis	Drug: Interferon beta -1b (Betaferon, BAY86-5046);Device: Betaconnect Autoinjector	Bayer	NULL	Completed	18 Years	N/A	All	162		Germany
6	NCT02247310 (ClinicalTrials.gov)	October 20, 2014	19/9/2014	BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon	BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®	Multiple Sclerosis, Relapsing Remitting	Drug: Interferon beta -1b (Betaferon®, BAY 86-5046);Device: BETACONNECT	Bayer	NULL	Completed	N/A	N/A	All	498	N/A	Austria;Belgium;Bosnia and Herzegovina;Croatia;Czechia;France;Greece;Hungary;Italy;Spain;Switzerland;Czech Republic;Netherlands
7	NCT02121444 (ClinicalTrials.gov)	June 23, 2014	22/4/2014	BAY86-5046 (Betaseron), Non Interventional Studies	BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®	Multiple Sclerosis	Drug: Interferon beta -1b (Betaferon, BAY 86-5046);Device: BETACONNECT auto-injector.	Bayer	NULL	Completed	18 Years	N/A	All	151	N/A	Germany

先頭へ